1. Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Noel W. Clarke 
European Urology Supplements 
Volume 5, Issue 17, Pages (October 2006)
DOI: /j.eursup
Copyright © 2006 European Association of Urology Terms and Conditions

2. Fig. 1
Bone loss is accelerated with androgen-deprivation therapy (ADT). Data from Kanis et al. [4] and Maillefert et al. [1].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

3. Fig. 2
Relative risk of fracture among men with prostate cancer. ADT=androgen-deprivation therapy; PC=prostate cancer; GnRH=gonadotropin-releasing hormone. Data from Smith et al. [9].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

4. Fig. 3
Fractures negatively correlate with survival in patients with prostate cancer. Adapted with permission from Oefelein et al. [12].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

5. Fig. 4
Communicating the results of the bone mineral density (BMD) test [17–20].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

6. Fig. 5
Identifying and treating bone loss in men with prostate cancer. ADT=androgen-deprivation therapy; BMD=bone mineral density; CT=computed tomography; DEXA=dual-energy x-ray absorptiometry. Adapted with permission from Diamond et al. [16].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions